Karyopharm Therapeutics | KPTI - Trade Creditors


Karyopharm Therapeutics reported $5.39M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
AbbVie USD 32.25B 1.2B Jun/2025
Abbott USD 4.12B 183M Sep/2025
Amgen USD 20.89B 1.25B Dec/2025
AstraZeneca USD 25.28B 252M Dec/2025
BioCryst Pharmaceuticals USD 5.57M 3.02M Sep/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Eli Lilly USD 4.26B 186.5M Sep/2025
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
GlaxoSmithKline GBP 15.38B 294M Dec/2025
Incyte USD 1.63B 1.46B Dec/2025
J&J USD 11.99B 2.37B Dec/2025
Karyopharm Therapeutics USD 5.39M 2.8M Sep/2025
MacroGenics USD 5.94M 1.28M Sep/2025
Merck USD 4.15B 102M Sep/2025
Nektar Therapeutics USD 15.56M 1.28M Sep/2025
Novartis USD 4.56B 49M Sep/2025
Novartis USD 4.56B 49M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Roche Holding CHF 5.78B 1.27B Dec/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Takeda JPY 467.59B 28.61B Dec/2025
Tectonic Therapeutic USD 1.48M 1.32M Sep/2025
TG Therapeutics USD 61.64M 72.38M Sep/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Xencor USD 9.08M 9.45M Sep/2025